Sales of respiratory medications key to predicting disease mortality, UK study finds

The value of integrating national longitudinal shopping data into respiratory disease forecasting models.

Latigo secures $150m for non-opioid pain treatment development

The company has recently shared Phase I outcomes for an orally administered candidate for non-opioid pain relief. Credit: meeboonstudio/Shutterstock. Latigo Biotherapeutics has secured $150m in

March 17, 2025

J&J expands dermatology portfolio with $850m Proteologix acquisition – Pharmaceutical Technology

J&J will gain access to Proteologix’s PX128 and PX130 for the treatment of atopic dermatitis. Credits: Skorzewiak/Shutterstock.com In a bid to solidify its footing in

May 17, 2024

Study explores cancer risks of hormonal contraceptives

Many women worry hormonal contraceptives have dangerous side-effects including increased cancer risk. But this perception is often out of proportion with the actual risks.

January 15, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.